Roche Applied
Science (SWX:RO) (SWX:ROG) (Pink Sheets: RHHBY) will announce the European
and Asia Pacific launch of the NimbleGen CGX arrays for microarray-based cytogenetic
analysis at a workshop series in four European cities and seven cities in Asia
Pacific. The CGX arrays are designed by Signature Genomic Laboratories (Signature
Genomics) and provide high-resolution, genome-wide analysis of chromosomal abnormalities.
Roche NimbleGen will provide arrays with the Signature Genomics design in multiplex
array formats to accommodate the simultaneous processing and analysis of 3,
6, or 12 samples. The CGX arrays are supported by a comprehensive microarray
workflow from Roche that includes NimbleGen reagents and instrumentation. Signature
Genomics will offer full support for data analysis using its Genoglyphix®
software.
Dr. Lisa G. Shaffer, President and CEO of Signature Genomics and keynote speaker
at the workshop events in Europe said, “As one of the pioneers in the
field of genomic analysis, we continuously work toward innovation and improvement
in the products and services we provide. We feel that the Roche partnership
is a synergistic fit between two great organizations. Like us, Roche is focused
on technical excellence and delivering valuable and relevant scientific information.”
“We, at Roche, are excited to be partnering with Signature Genomics,
the market leader in molecular cytogenetic analysis,” said Dr. Gerd Maass,
CEO of Roche NimbleGen. “This collaboration signifies Roche’s incredible
progress in the last year towards designing and manufacturing high-quality microarrays
with supporting comprehensive workflow solutions that meet the specific needs
of researchers in the field of genetic analysis.”
For more information about Roche NimbleGen, please access the company’s
website at: www.nimblegen.com.
Posted November 2nd, 2009
